Publikasjoner
Vitenskapelig artikkel
- Christopher Elnan Kvistad; Torbjørn Kråkenes; Trygve Holmøy et al. (2026). Intrathecal Mesenchymal Stem Cells in Progressive Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Trial (SMART-MS). (ekstern lenke)
- Tilde Harridsleff Rasmussen; Stine Schikora-Rustad; Åslaug Rudjord Lorentzen et al. (2026). Low risk of severe COVID-19 in vaccinated people with multiple sclerosis: a nationwide Norwegian study. (ekstern lenke)
- Marie Ytterdal; Casper Eugen Sandvik; Trygve Holmøy et al. (2026). The neural transdifferentiation potential of bone marrow mesenchymal stem cells. (ekstern lenke)
- Simen Berg Saksvik; Liv Marie Rønhovde; Kristine Lynum et al. (2025). Digital cognitive behavioral therapy for insomnia compared with digital patient education about insomnia in people with multiple sclerosis in Norway: study protocol for a randomized controlled trial. (ekstern lenke)
- Hanne Marie Lunde; Øivind Torkildsen; Lars Bø et al. (2016). Botulinum Toxin as Monotherapy in Symptomatic Trigeminal Neuralgia. (ekstern lenke)
- Torbjørn Kråkenes; Stig Wergeland; Niyaz Abdulbaqi Abdulmajid Al-Sharabi et al. (2023). The neuroprotective potential of mesenchymal stem cells from bone marrow and human exfoliated deciduous teeth in a murine model of demyelination. (ekstern lenke)
- Katharina Natalie Gottschlich; Zinajda Zolic-Karlsson; Eline Aas et al. (2024). Healthcare utilization and costs associated with autologous haematopoietic stem cell transplantation in Norwegian patients with relapsing remitting multiple sclerosis. (ekstern lenke)
- Silje Agnethe Stokke; Joachim Burman; Anne Kristine Lehmann et al. (2022). Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT. (ekstern lenke)
- Stig Wergeland; Øivind Torkildsen; Kjell-Morten Myhr et al. (2012). The cuprizone model: regional heterogeneity of pathology. (ekstern lenke)
- John W. Peterson; Lars Bø; Sverre Mørk et al. (2001). Transected Neurites, Apoptotic Neurons and Reduced Inflammation in Cortical MS Lesions. (ekstern lenke)
- Evert-Jan Kooi; Jack van Horssen; Maarten Witte et al. (2009). Abundant extracellular myelin in the meninges of patients with multiple sclerosis. (ekstern lenke)
- Lars Bø; Sverre Mørk; Jeroen J.G. Geurts et al. (2006). Grey matter pathology in multiple sclerosis. (ekstern lenke)
- Sveinung Fjær; Lars Bø; Kjell-Morten Myhr et al. (2015). Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model. (ekstern lenke)
- Hanne Marie Lunde; Tommy Frøseth Aae; William Indrevåg et al. (2012). Poor Sleep in Patients with Multiple Sclerosis. (ekstern lenke)
- Christopher P. Gilmore; Jeroen J.G. Geurts; Nikos Evangelou et al. (2009). Spinal cord grey matter lesions in multiple sclerosis detected by post-mortem high field MR imaging. (ekstern lenke)
- Hanne Marie Lunde; Wenche Telstad; Nina Agnethe Grytten et al. (2014). Employment among patients with multiple sclerosis-A population study. (ekstern lenke)
- Agnes Elisabeth Nystad; Stig Wergeland; Lage Aksnes et al. (2014). Effect of high-dose 1.25 dihydroxyvitamin D3 on remyelination in the cuprizone model. (ekstern lenke)
- Øivind Fredvik Torkildsen; Linn Anne Brunborg; Frits Alan Thorsen et al. (2009). Effects of dietary intervention on MRI activity, de- and remyelination in the cuprizone model for demyelination. (ekstern lenke)
- Jack van Horssen; Bianca P. Brink; Helga E. de Vries et al. (2007). The blood-brain barrier in cortical multiple sclerosis lesions. (ekstern lenke)
- Tomas Kalincik; Sifat Sharmin; Izanne Roos et al. (2024). Effectiveness of autologous haematopoietic stem cell transplantation versus natalizumab in progressive multiple sclerosis. (ekstern lenke)
- Maarten Witte; Lars Bø; Richard J. Rodenburg et al. (2009). Enhanced number and activity of mitochondria in multiple sclerosis lesions. (ekstern lenke)
- Sonia Gavasso; Jonas Bull Haugsøen; Dimitrios Kleftogiannis et al. (2025). High-dimensional Immune Profiling Following Autologous Hematopoietic Stem Cell Transplantation in Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)
- Fredrik Romi; Lars Bø; Geir Olve Skeie et al. (2002). Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with co-stimulatory molecules. (ekstern lenke)
- Christopher P. Gilmore; GC DeLuca; Lars Bø et al. (2009). Spinal Cord Neuronal Pathology in Multiple Sclerosis. (ekstern lenke)
- Maria Nordheim Alme; Agnes Elisabeth Nystad; Lars Bø et al. (2015). Fingolimod does not enhance cerebellar remyelination in the cuprizone model. (ekstern lenke)
- Agnes Elisabeth Nystad; Ragnhild Reehorst Lereim; Stig Wergeland et al. (2019). Fingolimod downregulates brain sphingosine-1-phosphate receptor 1 levels but does not promote remyelination or neuroprotection in the cuprizone model. (ekstern lenke)
- Stig Wergeland; Øivind Torkildsen; Kjell-Morten Myhr et al. (2011). Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. (ekstern lenke)
- Christopher P. Gilmore; I Donaldson; Lars Bø et al. (2009). Regional variations in the extent and pattern of grey matter demyelination in multiple sclerosis: a comparison between the cerebral cortex, cerebellar cortex, deep grey matter nuclei and the spinal cord. (ekstern lenke)
- Esther C.W. Breij; Bianca P. Brink; Rob Veerhuis et al. (2008). Homogeneity of active demyelinating lesions in established multiple sclerosis. (ekstern lenke)
- Ingrid Anne Lie; Emma Kerklingh; Kristin Wesnes et al. (2022). The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis. (ekstern lenke)
- Hilde Marie Torgauten; Kjell-Morten Myhr; Stig Wergeland et al. (2021). Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study. (ekstern lenke)
- Christopher Elnan Kvistad; Anne Kristine Lehmann; Silje Agnethe Stokke et al. (2024). Autologous hematopoietic stem cell transplantation for multiple sclerosis: Long-term follow-up data from Norway. (ekstern lenke)
- Hanne Marie Lunde; Jörg Assmus; Kjell-Morten Myhr et al. (2017). Survival and cause of death in multiple sclerosis: A 60-year longitudinal population study. (ekstern lenke)
- Lars Bø; C. Vedeler; Harald Inge Nyland et al. (2003). Intracortical demyelination in multiple sclerosis is not associated with increased lymphocyte infiltration. (ekstern lenke)
- Lars Bø; C. Vedeler; Harald Inge Nyland et al. (2003). Subpial demyelination in the cerebral cortex of multiple sclerosis. (ekstern lenke)
- Jeroen J.G. Geurts; Lars Bø; Lars Bö et al. (2007). Extensive hippocampal demyelination in multiple sclerosis. (ekstern lenke)
- BD Trapp; Lars Bø; Sverre Mørk et al. (1999). Pathogenesis of tissue injury in MS lesions. (ekstern lenke)
- Sveinung Fjær; Lars Bø; Arvid Lundervold et al. (2013). Deep gray matter demyelination detected by magnetization transfer ratio in the cuprizone model. (ekstern lenke)
- Emma C. Tallantyre; Lars Bø; Omar Al-Rawashdeh et al. (2009). Greater loss of axons in primary progressive multiple sclerosis plaques compared to secondary progressive disease. (ekstern lenke)
- Tomas Kalincik; Sifat Sharmin; Izanne Roos et al. (2023). Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)
- Øivind Fredvik Torkildsen; Linn Anne Bjelland Brunborg; Kjell-Morten Myhr et al. (2008). The cuprizone model for demyelination. (ekstern lenke)
- Øivind Torkildsen; Kjell-Morten Myhr; Lars Bø (2016). Disease-modifying treatments for multiple sclerosis – a review of approved medications. (ekstern lenke)
- Intakhar Ahmad; Stig Wergeland; Eystein Oveland et al. (2023). An Association of Chitinase-3 Like-Protein-1 With Neuronal Deterioration in Multiple Sclerosis. (ekstern lenke)
- Maria Therese Fossum; Hilde Marie Torgauten; Jan Harald Aarseth et al. (2025). Early extended interval dosing of rituximab in multiple sclerosis: A comparative cohort study on efficacy and safety. (ekstern lenke)
- Evert-Jan Kooi; Jeroen J.G. Geurts; Jack van Horssen et al. (2009). Meningeal inflammation is not associated with cortical demyelination in chronic multiple sclerosis. (ekstern lenke)
- Brit Ellen Rød; Øivind Torkildsen; Kjell-Morten Myhr et al. (2022). Safety of breast feeding during rituximab treatment in multiple sclerosis. (ekstern lenke)
- Øivind Fredvik Torkildsen; Linn Anne Brunborg; Anne Marita Milde et al. (2009). A salmon based diet protects mice from behavioural changes in the cuprizone model for demyelination. (ekstern lenke)
- Lars Bø; Jeroen J.G. Geurts; Paul van der Valk et al. (2007). Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. (ekstern lenke)
- Eystein Oveland; Intakhar Ahmad; Ragnhild Reehorst Lereim et al. (2021). Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis. (ekstern lenke)
- Jakob Rishovd Karlowicz; Mattias Klakegg; Jan Harald Aarseth et al. (2023). Predictors of hospitalization due to infection in rituximab-treated MS patients. (ekstern lenke)
- Ingrid Anne Lie; Kristin Wesnes; Silje Agnethe Stokke Kvistad et al. (2022). The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)
- Intakhar Ahmad; Stig Wergeland; Eystein Oveland et al. (2021). A higher proportion of ermin-immunopositive oligodendrocytes in areas of remyelination. (ekstern lenke)
- Nicholas Couturier; Jacques P. Zappulla; Valérie Lauwers-Cances et al. (2008). Mast cell transcripts are increased within and outside multiple sclerosis lesions. (ekstern lenke)
- Kjell-Morten Myhr; Nina Agnethe Grytten; Øivind Torkildsen et al. (2012). A need for national registries and international collaborative research in multiple sclerosis. (ekstern lenke)
- Trygve Holmøy; Børre Fevang; David Benee Olsen et al. (2019). Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis. (ekstern lenke)
- Silje Agnethe Stokke; Anne Kristine Lehmann; Linn Trovik et al. (2019). Safety and efficacy of autologous hematopoietic stem cell transplantation for multiple sclerosis in Norway. (ekstern lenke)
- Ingrid Anne Lie; Sezgi Kacar; Kristin Wesnes et al. (2022). Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. (ekstern lenke)
- Bjørn Svendsen; Nina Grytten; Lars Bø et al. (2018). The economic impact of multiple sclerosis to the patients and their families in Norway. (ekstern lenke)
- J.W Peterson; Lars Bø; Sverre Mørk et al. (2002). VCAM-1-positive microglia target oligodendrycytes at the border of multiple sclerosis lesions. (ekstern lenke)
- Emma C. Tallantyre; Lars Bø; Omar Al-Rawashdeh et al. (2010). Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. (ekstern lenke)
- Øivind Fredvik Torkildsen; Christine Stansberg; Solveig Mjelstad Angelskår et al. (2010). Upregulation of immunoglobulin-related genes in cortical sections from multiple sclerosis patients. (ekstern lenke)
Fagartikkel
Konferanseposter
- Linn Elin Rødal; Tori Smedal; Stig Wergeland et al. (2025). Tidlig screening av blæredysfunksjon ved multippel sklerose - et kvalitetsforbedringsprosjekt. (ekstern lenke)
- Sveinung Fjær; Stig Wergeland; Lars Bø (2014). Magnetization transfer ratio (MTR) increased unexpectedly in EAE induced mice.. (ekstern lenke)
- Marton König; Asia-Sophia Fumika Michaela Wolf; Anthony Ravussin et al. (2022). Immunogenicity and efficacy of mRNA-COVID-19 vaccines in people with multiple sclerosis. (ekstern lenke)
- Sonia Gavasso; Jonas Bull Haugsøen; Dimitrios Kleftogiannis et al. (2024). Short-Term and Long-Term Impact of Autologous Haematopoietic Stem Cell Transplantation on Immune Profiles in Relapsing-Remitting Multiple Sclerosis. (ekstern lenke)
Vitenskapelig litteraturgjennomgang
- Christopher Elnan Kvistad; Torbjørn Kråkenes; Gudveig Cecilie Gjerde Gjengedal et al. (2022). Safety and Clinical Efficacy of Mesenchymal Stem Cell Treatment in Traumatic Spinal Cord Injury, Multiple Sclerosis and Ischemic Stroke – A Systematic Review and Meta-Analysis. (ekstern lenke)
- Stig Wergeland; Øivind Torkildsen; Lars Bø et al. (2012). Polyunsaturated fatty acids in multiple sclerosis therapy. (ekstern lenke)
- Ingrid Anne Lie; Merlin M. Weeda; Rozemarijn M. Mattiesing et al. (2022). Relationship between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis. (ekstern lenke)
- Hanne Marie Lunde; Bjørn Bjorvatn; Kjell-Morten Myhr et al. (2013). Clinical assessment and management of sleep disorders in multiple sclerosis: a literature review. (ekstern lenke)
- Lars Bø (2009). The histopathology of grey matter demyelination in multiple sclerosis. (ekstern lenke)
- Torbjørn Kråkenes; Casper Eugen Sandvik; Marie Ytterdal et al. (2024). The Therapeutic Potential of Exosomes from Mesenchymal Stem Cells in Multiple Sclerosis. (ekstern lenke)
- Christopher Elnan Kvistad; Torbjørn Kråkenes; Sonia Gavasso et al. (2024). Neural regeneration in the human central nervous system—from understanding the underlying mechanisms to developing treatments. Where do we stand today?. (ekstern lenke)
- Paolo A. Muraro; Alice Mariottini; Raffaella Greco et al. (2025). Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder - recommendations from ECTRIMS and the EBMT. (ekstern lenke)
- Kjell-Morten Myhr; Øivind Torkildsen; Peter Andreas Vold Lossius et al. (2019). B cell depletion in the treatment of multiple sclerosis. (ekstern lenke)
- Kjell-Morten Myhr; Nina Grytten; Øivind Torkildsen et al. (2015). The Norwegian Multiple Sclerosis Registry and Biobank. (ekstern lenke)
Konferanseabstrakt
- Maarten Witte; Lars Bø; Richard J. Rodenburg et al. (2009). MITOCHONDRIAL ALTERATIONS IN ASTROCYTES IN MS LESIONS. (ekstern lenke)
- Evert-Jan Kooi; Lars Bø; Jack van Horssen et al. (2008). Meningeal inflammation in multiple sclerosis. (ekstern lenke)
- Emma C. Tallantyre; Lars Bø; James Lowe et al. (2009). Equal loss of corticospinal axons despite less demyelination in primary vs secondary progressive multiple sclerosis. (ekstern lenke)
- Stig Wergeland; Øivind Fredvik Torkildsen; Kjell-Morten Myhr et al. (2009). Histopathological characterisation of the cuprizone model for demyelination. (ekstern lenke)
- Esther C.W. Breij; Bianca P. Brink; Rob Veerhuis et al. (2008). A homogeneous pattern of active demyelination in patients with established multiple sclerosis. (ekstern lenke)
- Evert-Jan Kooi; Jack van Horssen; Maarten Witte et al. (2008). Extensive myelin deposition in the meninges of patients with multiple sclerosis. (ekstern lenke)
- Øivind Fredvik Torkildsen; Linn Anne Bjelland Brunborg; Anne Marita Milde et al. (2008). Fish diet prevents impaired mobility in the murine cuprizone model for multiple sclerosis. (ekstern lenke)
- Hanne Marie Lunde; Tommy F Aae; William Indrevåg et al. (2012). Poor sleep in patients with multiple sclerosis. (ekstern lenke)
Doktorgradsavhandling
- Lars Bø (1998). Multiple sclerosis, immunopathological studies of inflammatory control nervous system demyelination. (ekstern lenke)
- Hanne Marie Bøe Lunde; Lars Bø (2017). Patient-centered outcomes in multiple sclerosis. Results from observational studies on sleep, employment and survival. (ekstern lenke)
Fremhevet artikkel i media
Konferanseforedrag
- Lars Bø (2001). Differences in pathology between secondary and primary multiple sclerosis. (ekstern lenke)
- Lars Bø (2001). Normal appearing cortical tissue, pathology studies. (ekstern lenke)
- Fredrik Romi; Lars Bø; Geir Olve Skeie et al. (2002). Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with co-stimulatory molecules. (ekstern lenke)